Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus
Conditions
Interventions
Current interventions as of 27/08/2020:
This study will include people known to be not regularly taking their prescribed tablets or capsules for managing their type 2 diabetes. These p
Sponsors
University of East Anglia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. People with T2DM prescribed oral blood glucose lowering medication that are non-adherent to oral blood glucose and/or blood pressure lowering drugs 2. Aged 35-75 years 3. Smartphone user and willing to use platform facilities (digital health resources) or have access to an electronic device (e.g. computer) 4. All ethnicities 5. Able to understand text messages in English
Exclusion criteria
Exclusion criteria: 1. People with T2DM that use parenteral medication (e.g. insulin) for diabetes 2. People in which, according to screening data collected, adherence data is not valid due to hospital admission or in which medication is dispensed by different pharmacies 3. People who use medication-intake supporting services provided by the pharmacy (i.e. repeat dispensing and pill packaging) 4. People who indicate in the questionnaire that they suffer from the following major mental health disorders: depression, schizophrenia, psychosis or suicidality 5. Any significant medical reason for exclusion as determined by the researchers 6. Unable or not willing to provide written informed consent 7. Not willing to accept information transfer concerning participation in the study, and/or information regarding a participants’ health (like laboratory results or physical examination) and/or eventual adverse events to and from his GP and/or pharmacist 8. People who are involved in current research or have recently been involved in any research prior to recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medication adherence measured with a telephone pill count at baseline and the end of the trial (after 6 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Blood pressure measured by the GP at baseline, 3 and 6 months 2. HbA1c level measured by the GP at baseline, 3 and 6 months 3. Medication adherence measured using Medication Adherence Report Scale (MARS-5) questionnaire at baseline, 3 and 6 months 4. Attitude and beliefs toward medication measured using Beliefs about medicines questionnaire (BMQ specific questionnaire) at baseline, 3 and 6 months 5. Satisfaction with diabetes treatment measured using Diabetes Treatment Satisfaction Questionnaire (DTSQs+c) at baseline, 3 and 6 months 6. Quality of life measured using Quality of Life Questionnaire (EQ-5D-5L) at baseline, 3 and 6 months 7. Medical and productivity costs measured using Institute of Medical Technology Assessment (iMTA costs questionnaire) at 3 and 6 months | — |
Countries
England, Netherlands, United Kingdom
Contacts
Public ContactDebi Bhattacharya
Outcome results
None listed